Holen Sie sich die Stockscreener-App
6.31
2.62%
-0.17
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.48
Offen:
$6.57
24-Stunden-Volumen:
658.60K
Relative Volume:
0.62
Marktkapitalisierung:
$588.18M
Einnahmen:
$823.60M
Nettoeinkommen (Verlust:
$-116.00M
KGV:
-4.8538
EPS:
-1.3
Netto-Cashflow:
$-107.30M
1W Leistung:
-6.66%
1M Leistung:
-17.30%
6M Leistung:
+20.19%
1J Leistung:
-52.98%
1-Tages-Spanne:
$6.29
$6.57
1-Wochen-Bereich:
$6.29
$6.77
52-Wochen-Spanne:
$3.76
$15.47
Myriad Genetics Inc Stock (MYGN) Company Profile
Firmenname
Myriad Genetics Inc
Sektor
Branche
Telefon
801-584-3600
Adresse
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Vergleichen Sie MYGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
6.31 | 604.02M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
585.07 | 218.19B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
230.63 | 162.69B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
687.89 | 54.98B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
137.93 | 39.23B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
227.11 | 38.64B | 15.90B | 1.28B | 2.21B | 7.2842 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-10 | Eingeleitet | UBS | Neutral |
| 2024-12-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Underperform |
| 2024-05-08 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Underweight |
| 2023-05-23 | Hochstufung | Goldman | Sell → Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Eingeleitet | Stephens | Equal-Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Sell |
| 2019-09-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Herabstufung | Needham | Strong Buy → Hold |
| 2019-07-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-03-12 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
| 2018-11-30 | Hochstufung | Goldman | Sell → Neutral |
| 2018-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Eingeleitet | Goldman | Sell |
| 2018-01-22 | Bestätigt | Barclays | Equal Weight |
| 2018-01-05 | Eingeleitet | BTIG Research | Buy |
| 2017-10-02 | Fortgesetzt | Leerink Partners | Mkt Perform |
| 2017-08-09 | Bestätigt | Barclays | Equal Weight |
| 2017-02-08 | Hochstufung | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Sell |
| 2016-10-10 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
Alle ansehen
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
Should Myriad Genetics Stock Stay in Your Portfolio Right Now? - Zacks Investment Research
Pancreatic Cancer Market is projected to reach US$ 5.7 billion - openPR.com
Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay - MSN
Looking at the Narrative for Myriad Genetics After Price Target Revisions and Growth Concerns - Yahoo Finance
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Finviz
Can Myriad Genetics Inc. stock sustain revenue growth2025 Macro Impact & Low Volatility Stock Recommendations - Улправда
Is Myriad Genetics Inc a good long term investmentPrice Volatility Patterns & Don’t Miss These Undervalued Stocks - earlytimes.in
Avoiding Lag: Real-Time Signals in (MYGN) Movement - news.stocktradersdaily.com
Myriad Genetics, Inc. $MYGN Shares Bought by Assenagon Asset Management S.A. - MarketBeat
What insider trading reveals about Myriad Genetics Inc. stockMarket Performance Recap & Intraday High Probability Alerts - Улправда
Sell Signal: Can Myriad Genetics Inc. (MYD) stock surprise with quarterly results2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - Улправда
Is Myriad Genetics Inc. stock vulnerable to regulatory risksEarnings Overview Report & AI Powered Market Entry Strategies - Улправда
Will Myriad Genetics Inc. stock attract more institutional investorsWeekly Trend Recap & Capital Efficient Trading Techniques - Улправда
Why Myriad Genetics Inc. stock is in analyst buy zoneOptions Play & Daily Entry Point Trade Alerts - Улправда
Can Myriad Genetics Inc. stock outperform in 2025 bull marketQuarterly Trade Report & Community Verified Watchlist Alerts - DonanımHaber
Myriad Genetics, Inc. (NASDAQ:MYGN) Looks Inexpensive But Perhaps Not Attractive Enough - 富途牛牛
Can Myriad Genetics Inc. (MYD) stock surprise with quarterly resultsMarket Performance Recap & Technical Pattern Alert System - Улправда
Will Myriad Genetics Inc. stock benefit from infrastructure spendingQuarterly Earnings Summary & AI Optimized Trade Strategies - DonanımHaber
Zydus Lifesciences signs agreement with Myriad Genetics for cancer-risk tests in India - marketscreener.com
J.P. Morgan Healthcare Conference - marketscreener.com
Parp Inhibitor Biomarkers Market Forecast Through 2032 - openPR.com
Cancer Diagnostics Market is Going to Boom: New Report Reveals - openPR.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Myriad Genetics Earnings Notes - Trefis
Published on: 2025-12-16 07:23:24 - earlytimes.in
Chart Watch: Why Myriad Genetics Inc stock could rally in 2025Weekly Investment Report & Low Drawdown Trading Strategies - moha.gov.vn
Myriad Genetics (MYGN) CEO discloses 29,634-share tax withholding - Stock Titan
Will Breakout in GIC Housing Finance Limited Sustain Through Next WeekCapital Gains Strategies & Free Unmatched Market Gains - earlytimes.in
Myriad Genetics, Inc. $MYGN Stake Reduced by Camber Capital Management LP - MarketBeat
Myriad Genetics Q3 2025 Earnings Preview - MSN
Discipline and Rules-Based Execution in MYGN Response - news.stocktradersdaily.com
Why Myriad Genetics (MYGN) Stock Is Up Today - Finviz
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium - The Manila Times
Myriad Genetics to Showcase Advances in Hereditary Cancer and MRD Testing at 2025 San Antonio Breast Cancer Symposium - Quiver Quantitative
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q3 Earnings? - Yahoo Finance
Prudential Financial Inc. Has $1.82 Million Stock Position in Myriad Genetics, Inc. $MYGN - MarketBeat
Fisher Asset Management LLC Purchases 219,607 Shares of Myriad Genetics, Inc. $MYGN - MarketBeat
What MACD trends signal for Myriad Genetics Inc. (MYD) stock2025 Market Sentiment & Free Reliable Trade Execution Plans - Newser
Why Myriad Genetics Inc. stock appeals to analystsWeekly Trend Summary & Free Expert Approved Momentum Trade Ideas - Newser
Can Myriad Genetics Inc. stock continue upward trendMarket Trend Review & Low Drawdown Trading Techniques - Newser
Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report? - MSN
Upcoming Virtual Meeting on December 11 Hosted by Craig-Hallum f - GuruFocus
4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial - GlobeNewswire Inc.
1 Healthcare Stock with Promising Prospects and 2 We Question - Barchart.com
How Myriad Genetics Inc. stock benefits from strong dollarTrade Risk Assessment & Low Drawdown Investment Ideas - Newser
Why Myriad Genetics (MYGN) Stock Is Trading Lower Today - Finviz
Myriad Genetics, Inc. $MYGN Stock Holdings Lifted by XTX Topco Ltd - MarketBeat
Myriad Genetics Outpaces Expectations But Faces Profit Challenges - Finimize
Finanzdaten der Myriad Genetics Inc-Aktie (MYGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.35%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):